


Advanced methods for matchingadjusted indirect comparison

Antonio Remiro-Azócar, PhD Methods & Outreach, Novo Nordisk ISPOR 2024, Atlanta 8th May 2024



Agenda


- 1. Background
- 2. Matching-adjusted indirect comparison
- 3. Two-stage matching-adjusted indirect comparison
- 4. Weight truncation
- 5. Simulation study
- 6. Alternative variance reduction approaches
- 7. Concluding remarks

Background

Covariate-adjusted indirect treatment comparisons (ITCs)


The following setting is common in health technology assessment:

- An active treatment (treatment A) needs to be compared against a competitor (treatment B)
- No head-to-head trial between treatments *A* (*T*=1) and *B* (*T*=2)
- We have individual patient data (IPD) for study A ("index" study) but not for study B ("competitor" study)
- There are differences in baseline characteristics between study A (S=1) and study B (S=2)
- Transportability problem: transfer inferences from study A to study B for an unbiased ITC in study B



ANCHORED COMPARISON

UNANCHORED COMPARISON




Background


Covariate-adjusted indirect treatment comparisons (ITCs)

Matching-adjusted indirect comparison (MAIC):

- The most widely used covariate-adjusted ITC method
- Weighting approach: the IPD is weighted so that there is cross-study balance in covariate moments
- Vulnerable to poor precision where covariate overlap is poor and the effective sample size after weighting is small, in which case a few extreme weights have an undue impact
- The above scenarios are pervasive in health technology appraisals



ANCHORED COMPARISON



UNANCHORED COMPARISON

Matching-adjusted indirect comparison (MAIC)

• Logistic model for trial assignment

$$\mathbf{n}(w_i) = \ln[w(\mathbf{z}_i)] = \ln\left[\frac{Pr(S=2 \mid \mathbf{z}_i)}{1 - Pr(S=2 \mid \mathbf{z}_i)}\right] = \alpha_0 + \mathbf{z}_i \boldsymbol{\alpha}_1$$

• Entropy balancing approach; covariate balance is viewed as a convex optimization problem

$$Q(\boldsymbol{\alpha}_1) = \sum_{i=1}^n \exp\left(\boldsymbol{z}_i^* \boldsymbol{\alpha}_1\right) \qquad \boldsymbol{z}_i^* = \boldsymbol{z}_i - \boldsymbol{\theta}_{\boldsymbol{z}_i}$$

• The estimated weights represent the conditional odds of assignment to study *B*

$$\hat{w}_i = \exp(\boldsymbol{z}_i^* \hat{\boldsymbol{\alpha}}_1)$$

• Marginal mean outcomes and/or relative effects for study A treatment(s) estimated in study B

$$\hat{\mu}_{t}^{(2)} = \frac{\sum_{i=1}^{n_{t}} y_{i,t} \hat{w}_{i,t}}{\sum_{i=1}^{n_{t}} \hat{w}_{i,t}} \qquad \qquad \hat{\Delta}_{10}^{(2)} = g\left(\hat{\mu}_{1}^{(2)}\right) - g\left(\hat{\mu}_{0}^{(2)}\right)$$

- The objective of the "odds weights" is to account for covariate differences and attain balance **across studies**
- Key assumptions: conditional transportability and overlap across studies

Two-stage matching-adjusted indirect comparison (2SMAIC) *Modular extension to MAIC*

• Additional logistic model for treatment assignment in the index trial, fitted to the IPD

$$\operatorname{logit}[e_i] = \operatorname{logit}[e(\boldsymbol{x}_i)] = \operatorname{logit}[Pr(T = 1 \mid \boldsymbol{x}_i)] = \beta_0 + \boldsymbol{x}_i \boldsymbol{\beta}_1$$

• Having fitted the model, e.g., using maximum-likelihood, predict propensity scores

 $\hat{e}_i = \operatorname{expit}[\hat{\beta}_0 + \boldsymbol{x}_i \hat{\boldsymbol{\beta}}_1]$

• Estimate "inverse probability of treatment" weights (IPTWs) and combine them with the odds weights

$$\hat{\omega}_{i} = \frac{t_{i}\hat{w}_{i}}{\hat{e}_{i}} + \frac{(1-t_{i})\hat{w}_{i}}{(1-\hat{e}_{i})}$$
$$\hat{\mu}_{t}^{(2)} = \frac{\sum_{i=1}^{n_{t}} y_{i,t}\hat{\omega}_{i,t}}{\sum_{i=1}^{n_{t}} \hat{\omega}_{i,t}} \qquad \qquad \hat{\Delta}_{10}^{(2)} = g\left(\hat{\mu}_{1}^{(2)}\right) - g\left(\hat{\mu}_{0}^{(2)}\right)$$

- The IPTWs seek to balance covariates between the index trial treatment groups; the combined weights seek to attain balance between the index trial treatment groups and across studies
- Limitation: because it relies on a treatment assignment model for the index trial, 2SMAIC is not applicable in the unanchored case

Rationale for 2SMAIC with index RCT

- In an RCT, the true treatment assignment mechanism and propensity scores are fixed and known, due to randomization
- Randomization guarantees covariate balance on expectation, in large samples
- Senn (2004): "over all randomizations the groups are balanced; for a particular randomization they are unbalanced" there may still be finite-sample imbalances due to chance
- Estimating the propensity scores is beneficial to correct for residual imbalances between treatment arms, particularly where the index trial sample size is small
- Motivation for covariate adjustment: to increase efficiency by gaining precision, not to reduce bias!

Rationale for 2SMAIC with observational index study

- One no longer relies on the internal validity of the index study; covariate adjustment between treatment arms is necessary for confounding control
- Strong assumption #1: conditional exchangeability over treatment assignment → compromised if the treatment assignment model excludes potential confounders
- Strong assumption #2: positivity of treatment assignment → compromised by deterministic positivity violations, such as different selection criteria into the treatment groups
- Randomization is no longer leveraged to meet the strong assumptions above
- Motivation for covariate adjustment: to reduce internal validity bias due to confounding

Truncation

A simple approach for variance reduction

- Restricts the influence of extreme weights by capping the highest estimated weights at a given percentile
- The ideal truncation level will vary on a case-by-case basis and can be set empirically, e.g. by progressively truncating the weights. Density plots are helpful to assess the dispersion of the weights and identify an optimal cutoff point.
- There is a clear trade-off from a bias-variance standpoint: precision improvements always come at the cost of sacrificing balance and accepting bias
- Prior transportability/generalizability literature uses a 95th percentile cutoff; lower thresholds further reduce variance at the cost of more bias and further shifting the target population or estimand
- Limitations:
- 1. Shifts the target estimand definition (population or analysis set attribute)
- 2. Requires arbitrary ad hoc decisions on cutoff thresholds

Simulation study

<u>Setting</u>

- Anchored indirect treatment comparison across two RCTs
- Small sample sizes for index trial ($N \in \{140, 200\}$)
- 3 strongly prognostic and effect-modifying covariates
- Varying levels of deterministic overlap between the target populations of the RCTs
- Continuous outcome, linear outcome generating model


<u>Methods</u>

- Standard matching-adjusted indirect comparison (MAIC)
- Two-stage matching-adjusted indirect comparison (2SMAIC)
- MAIC combined with weight truncation (T-MAIC), capping the estimated weights at the 95th percentile
- 2SMAIC combined with weight truncation (T-2SMAIC), capping the estimated weights at the 95th percentile

No unmeasured covariates and cross-study balance attained for all effect-modifying moments (means)

Simulation study results

- The two-stage approaches yield improved precision and efficiency with respect to their one-stage counterparts, with similar bias
- The two-stage approaches are more effective with lower index trial sample sizes, due to greater empirical imbalances between treatment arms
- The enhanced performance of the two-stage methods is strongly linked to the prognostic strength of covariates
- Performance gains of the two-stage approaches are attenuated where overlap is poor, due to high extremity of the weights




Advanced methods for matching-adjusted indirect comparison

Novo Nordisk[®]

Simulation study results

- With strong covariate overlap, truncation offers modest improvements in precision and efficiency, while inducing bias
- As overlap weakens, truncation notably improves precision by reducing the influence of extreme weights, but induces considerable bias
- The combination of the two-stage method and weight truncation (T-2SMAIC) offers the best performance in terms of precision and efficiency, with the increase in precision offsetting the increase in bias
- Truncation is less necessary and bias-variance trade-offs less favorable to variance reduction where there is good overlap, the weights are well-behaved and the effective sample size after weighting is sizeable



Advanced methods for matching-adjusted indirect comparison

Alternative variance reduction approaches

Jackson et al. (2021) weighting scheme

- Weight estimation procedure that satisfies the conventional method of moments while explicitly maximizing the effective sample size
- Minimizes dispersion of the weights, with more stable weights improving precision at the expense of inducing bias

<u>Reduce the number of moment-balancing conditions</u>

- Exclude less influential covariates
- Exclude higher-order moments, e.g., only balance means and not variances
- There are bias-variance trade-offs
- These options lead to increased overlap, lower likelihood of extreme weights, less drastic reductions in effective sample size and precision
- These options also lead to residual bias (Vo 2023), particularly as marginal treatment effects generally depend on the full joint covariate distribution, including that of purely prognostic covariates (Remiro-Azócar 2024)

Alternative variance reduction approaches

Weight trimming

- Excludes subjects with outlying weights
- Shares many of the limitations of truncation: arbitrary cutoff points, change in the estimand (target population/analysis set)
- Less appealing than truncation: information directly discarded \rightarrow precision loss

Weight stabilization

- Not applicable where the covariate-adjusted marginal effect is derived from the treatment coefficient of a weighted model of outcome on time-fixed binary treatment
- The fitted model is "saturated" (cannot be mis-specified)
- For saturated models, stabilized and unstabilized weights give identical results
- Potentially useful where the weighted outcome model is unsaturated, e.g., with dynamic or continuous-valued treatment regimens

Alternative variance reduction approaches

Overlap weighting

- Estimates treatment effects in a subsample with good overlap
- Challenging to implement where subject-level data are unavailable for the competitor study
- Also changes the population or analysis set attribute of the target estimand

Avoid weighting

- With weak overlap, methods based on modeling the outcome expectation, e.g., STC, model-based standardization (G-computation), ML-NMR, exhibit greater precision and efficiency than MAIC...
- ...but are prone to extrapolation, which may lead to severe bias under model misspecification (Vo 2023)
- Outcome modeling is a good option where feasible numerical solutions to MAIC do not exist due lack of covariate overlap

Concluding remarks

- We have explored two strategies to improve the precision and efficiency of MAIC:
 - 1. Modeling the treatment assignment mechanism in the index study
 - 2. Truncating the weights that are above a certain level
- Weighting is inherently modular:
 - 1. Just like we have combined the two-stage approach with truncation, other variance reduction approaches can be incorporated, potentially in combination
 - 2. The estimation procedure for the trial assignment weights does not necessarily need to be entropy balancing or method of moments, alternative methods could be used
 - 3. Further weighting modules could be incorporated to account for missingness and noncompliance, e.g., dropout or treatment switching, in the index trial

References

- Jackson, D., Rhodes, K. and Ouwens, M., 2021. Alternative weighting schemes when performing matching-adjusted indirect comparisons. Research Synthesis Methods, 12(3), pp.333-346
- Remiro-Azócar, A., 2022. Two-stage matching-adjusted indirect comparison. BMC medical research methodology, 22(1), p.217
- Remiro-Azócar, A., 2024. Transportability of model-based estimands in evidence synthesis. In press, Statistics in Medicine
- Senn, S., 2004. Controversies concerning randomization and additivity in clinical trials. Statistics in medicine, 23(24), pp.3729-3753
- Vo, T.T., 2023. A cautionary note on the use of G-computation in population adjustment. Research Synthesis Methods, 14(3), pp.338-341